Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
baloncibart
- Development stage
- Phase 2
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Baloncibart (REGN7544) is an investigational humanized IgG4-kappa monoclonal antibody developed by Regeneron Pharmaceuticals that acts as an antagonist of natriuretic peptide receptor 1 (NPR1, also known as NPRA or guanylate cyclase A). By blocking NPR1, baloncibart inhibits natriuretic peptide signaling, which prevents vasodilation and decreases renal sodium excretion, thereby restoring central blood volume and increasing blood pressure. The drug is being evaluated in Phase 2 clinical trials for the treatment of postural orthostatic tachycardia syndrome (POTS) and sepsis-induced hypotension.
02
Targets
NPR1 (Natriuretic peptide receptor 1)
Beyond the preview
Go deeper on baloncibart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on baloncibart.